Robert Stott

“While lifestyle interventions have yielded transient and modest effect sizes, surgical interventions [for obesity] have produced the

eosinophilic esophagitis at 48 weeks, according to data presented at the ACG Annual Scientific Meeting.

Key takeaways: No efficacy difference for IBD was found between infliximab-dyyb monotherapy or in combination with immunosuppressants.

primary biliary cholangitis , according to late-breaking data presented here.

injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting.

celiac disease , including anemia, iron deficiency and “continued mucosal damage in the small intestine,” according to a presenter.

Key takeaways: On-demand vonoprazan improved heartburn symptoms in nonerosive reflux disease within 1 hour of treatment.

SAN DIEGO — Glucagon-like peptide-1 receptor agonists may help alleviate risk for adverse liver outcomes, particularly hepatic decompensation, among patients with type 2 diabetes and alcohol-associated liver disease.

SAN DIEGO — Patients treated with once-monthly efimosfermin 300 mg achieved significant improvements in metabolic dysfunction-associated steatohepatitis resolution and fibrosis at 24 weeks, according to late-breaking data.

SAN DIEGO — Patients with diabetes who were prescribed glucagon-like peptide-1 receptor agonists had lower odds of metabolic dysfunction-associated